石药集团(01093)：石药创新(300765.SZ)一季度归母净利约7906.13万元同比减少38.86%

智通财经网04-22

智通财经APP讯，石药集团(01093)公布石药创新(300765.SZ)2024年第一季度业绩，营业收入约5.24亿元，同比减少27.08%;归属于上市公司股东的净利润约7906.13万元，同比减少38.86%;基本每股收益0.0676元。

公告称，营收减少主要原因为咖啡因产品价格较上年同期下降导致报告期内主营业务收入下降，同时上年同期巨石生物对Nectin4 ADC产品进行海外的开发及商业化授权，确认收入约3400万元。

净利减少主要原因为咖啡因产品价格下降，导致公司盈利下降，以及巨石生物主要管线尚在研发阶段，尚未贡献收入及利润。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2429210559?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_41.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2024-04-22 21:35","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2429210559","market":"hk","top_or_hot":-1,"title":"石药集团(01093)：石药创新(300765.SZ)一季度归母净利约7906.13万元 同比减少38.86%","media":"智通财经网","content":"<html><body><div> <p>智通财经APP讯，<a href=\"https://laohu8.com/S/01093\">石药集团</a>(01093)公布石药创新(300765.SZ)2024年第一季度业绩，营业收入约5.24亿元，同比减少27.08%;归属于上市公司股东的净利润约7906.13万元，同比减少38.86%;基本每股收益0.0676元。</p><p>公告称，营收减少主要原因为咖啡因产品价格较上年同期下降导致报告期内主营业务收入下降，同时上年同期巨石生物对Nectin4  ADC产品进行海外的开发及商业化授权，确认收入约3400万元。</p><p>净利减少主要原因为咖啡因产品价格下降，导致公司盈利下降，以及巨石生物主要管线尚在研发阶段，尚未贡献收入及利润。</p> <div></div> </div></body></html>","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药集团(01093)：石药创新(300765.SZ)一季度归母净利约7906.13万元 同比减少38.86%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药集团(01093)：石药创新(300765.SZ)一季度归母净利约7906.13万元 同比减少38.86%\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经网</strong><span class=\"h-time small\">2024-04-22 21:35</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div> <p>智通财经APP讯，<a href=\"https://laohu8.com/S/01093\">石药集团</a>(01093)公布石药创新(300765.SZ)2024年第一季度业绩，营业收入约5.24亿元，同比减少27.08%;归属于上市公司股东的净利润约7906.13万元，同比减少38.86%;基本每股收益0.0676元。</p><p>公告称，营收减少主要原因为咖啡因产品价格较上年同期下降导致报告期内主营业务收入下降，同时上年同期巨石生物对Nectin4  ADC产品进行海外的开发及商业化授权，确认收入约3400万元。</p><p>净利减少主要原因为咖啡因产品价格下降，导致公司盈利下降，以及巨石生物主要管线尚在研发阶段，尚未贡献收入及利润。</p> <div></div> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1107066.html\">智通财经网</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0226","symbol_name":"食品制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1107066.html","article_id":"2429210559","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_41.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429210559","pubTimestamp":1713792953,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"石药集团(01093)公布石药创新(300765.SZ)2024年第一季度业绩，营...","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300765":"新诺威","BK0226":"食品制造","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","01093":"石药集团","BK1191":"制药","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","BK1515":"抗疫概念","IE0008368742.USD":"首域中国增长基金I Acc","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK1521":"挪威政府全球养老基金持仓"},"translate_title":"CSPC (01093): CSPC Innovation (300765. SZ) 's net profit attributable to the parent company in the first quarter was about 79.0613 million yuan, a year-on-year decrease of 38.86%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300765":1,"01093":1},"content_text":"智通财经APP讯，石药集团(01093)公布石药创新(300765.SZ)2024年第一季度业绩，营业收入约5.24亿元，同比减少27.08%;归属于上市公司股东的净利润约7906.13万元，同比减少38.86%;基本每股收益0.0676元。公告称，营收减少主要原因为咖啡因产品价格较上年同期下降导致报告期内主营业务收入下降，同时上年同期巨石生物对Nectin4  ADC产品进行海外的开发及商业化授权，确认收入约3400万元。净利减少主要原因为咖啡因产品价格下降，导致公司盈利下降，以及巨石生物主要管线尚在研发阶段，尚未贡献收入及利润。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429210559"}

石药集团(01093)：石药创新(300765.SZ)一季度归母净利约7906.13万元 同比减少38.86%

精彩评论

石药集团(01093)：石药创新(300765.SZ)一季度归母净利约7906.13万元同比减少38.86%